Filters
The combination of bictegravir and lenacapavir, taken orally once daily, performed better than current complex treatment regimens in the phase II ARTISTRY-1 trial of people with HIV who are virologically suppressed.
The investigational RNAi therapeutic plozasiran significantly reduced triglyceride levels in individuals with severe hypertriglyceridaemia (SHTG) who were at high risk for pancreatitis, according to the final results of the phase IIb SHASTA-2 trial.
Adding desloratadine to an isotretinoin regimen appears to reduce pruritus in acne, leading to a higher patient satisfaction, as shown in a study.
The oral Janus kinase (JAK) 1 preferential inhibitor filgotinib appears to be safe and effective in the treatment of Asian patients with ulcerative colitis, according to real-world data.
Testosterone replacement therapy in men with hypogonadism does not appear to reduce the risk of developing diabetes, according to the results of the TRAVERSE* substudy.
Older adults who have undergone percutaneous coronary intervention (PCI) may do well with a shortened dual antiplatelet therapy (DAPT) duration, which has been shown to reduce the risk of bleeding without increasing the risk of adverse clinical events in a network meta-analysis.
The efficacy of benralizumab against severe eosinophilic asthma has been confirmed in an Asian population, with results consistent with the global data, as shown in the phase III MIRACLE trial.
Nonsteroidal anti-inflammatory drugs (NSAIDs) and combination treatments provide a more effective and safer alternatives to corticosteroid in the postoperative management of patients who have undergone cataract surgery, according to a study.
A novel device that integrates hexaminolevulinate (HAL) hydrochloride (HCl) with photodynamic therapy for the treatment of cervical histologic high-grade squamous intraepithelial lesions (HSIL) has shown good results in the global phase III APRICITY study, with lasting efficacy and an acceptable safety profile.
New drug applications approved by US FDA as of 16-31 March 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
